Allogeneic CAR-T achieves durable remissions in metastatic solid tumours
Allogene Therapeutics has announced the publication of complete Phase I data from the TRAVERSE study of ALLO-316 in advanced or metastatic renal cell carcinoma (RCC) in the Journal of Clinical Oncology.
TRAVERSE is being conducted as part of a five-year collaboration with The University of Texas MD Anderson Cancer Center.
ALLO-316, Allogene’s CD70-targeting AlloCAR-T investigational therapy incorporating the Dagger technology, achieved robust expansion, tumour infiltration, and durable antitumor activity in a solid tumour setting.
“TRAVERSE represents a potential breakthrough for both Allogene and the broader CAR-T field,” said Dr Zachary Roberts, President and Chief Executive Officer of Allogene. “CAR-T has transformed haematologic malignancies while solid tumours have remained one of the field’s most difficult challenges. When we designed ALLO-316 with the Dagger technology, our goal was to address two of the most persistent barriers in solid tumours – achieving robust CAR T expansion with standard lymphodepletion and translating that biology into durable responses.
“These results show that a well-designed allogeneic CAR-T product, developed for a defined population, can expand, persist, and produce durable responses in metastatic, treatment refractory solid tumours.”
All responders progression-free
Across the full Phase I TRAVERSE trial, 51 patients with Stage IV disease were enrolled, of whom 46 received ALLO-316 and had a median follow-up time of 28.8 months. The Phase Ib expansion cohort evaluated the safety and efficacy of the recommended Phase II regimen – ALLO-316 at a dose of 80M CAR-T cells following a standard FC lymphodepletion regimen and cyclophosphamide.
The 22 patients in the Phase Ib safety population all had RCC resistant to immune checkpoint blockers and at least one tyrosine kinase inhibitor (TKI), 82% had received ≥2 prior TKIs, and 41% had received prior belzutifan. Twenty of these patients received ALLO-316. Sixteen of the ALLO-316-treated patients in Phase Ib had a high CD70 Tumour Proportion Score (TPS ≥50%). The median time from enrolment to the start of therapy was four days.
“Most patients in TRAVERSE had exhausted available therapies and faced a poor prognosis, with survival often measured in months,” said Samer Srour, Associate Professor of Stem Cell Transplantation and Cellular Therapy at UT MD Anderson. “In that context, the depth and durability of responses observed with a one-time ALLO-316 infusion are very promising, particularly in patients with high CD70-expressing tumours where all responders remained progression-free at the time of the published analysis.”
A single dose of ALLO-316 produced disease control in half of patients in the Phase Ib cohort, with an overall confirmed response rate of 25% and a confirmed response rate of 31% in patients with CD70 TPS ≥50%. The median duration of response (mDOR) had not been reached, with the longest ongoing response exceeding 18 months. Median overall survival in the Phase Ib population was 15.2 months and was not estimable in the CD70-high group.
